{"organizations": [], "uuid": "b44580fd7e34e5c217a7ab20361d538c9d57eac6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-biohaven-says-us-fda-has-notified/brief-biohaven-says-u-s-fda-has-notified-co-it-may-proceed-with-clinical-investigation-of-bhv-5000-idUSFWN1PD06Y", "country": "US", "domain_rank": 408, "title": "BRIEF-Biohaven says U.S. FDA has notified co it may proceed with clinical investigation of BHV-5000", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-18T10:10:00.000+02:00", "replies_count": 0, "uuid": "b44580fd7e34e5c217a7ab20361d538c9d57eac6"}, "author": "", "url": "https://www.reuters.com/article/brief-biohaven-says-us-fda-has-notified/brief-biohaven-says-u-s-fda-has-notified-co-it-may-proceed-with-clinical-investigation-of-bhv-5000-idUSFWN1PD06Y", "ord_in_thread": 0, "title": "BRIEF-Biohaven says U.S. FDA has notified co it may proceed with clinical investigation of BHV-5000", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "brief-biohaven", "sentiment": "negative"}, {"name": "reuters) - biohaven pharmaceutical holding company ltd", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "nical", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 10 AM / Updated 14 minutes ago BRIEF-Biohaven says U.S. FDA has notified co it may proceed with clinical investigation of BHV-5000 Reuters Staff \nJan 18 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd: \n* BIOHAVEN ANNOUNCES INITIATION OF CLINICAL DEVELOPMENT FOR BHV-5000, A NOVEL LOW-TRAPPING NMDA ANTAGONIST \n* BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD- U.S. FOOD AND DRUG ADMINISTRATION HAS NOTIFIED CO IT MAY PROCEED WITH CLINICAL INVESTIGATION OF BHV-5000â€‹ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-18T10:10:00.000+02:00", "crawled": "2018-01-18T10:38:04.001+02:00", "highlightTitle": ""}